Drugs / AL101
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04973683 | Sep 2021 → Jun 2026 | adenoid cystic carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT04111666 | Dec 2019 → Jun 2022 | — | Alector Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01653470 | Oct 2012 → May 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01363817 | Sep 2011 → Feb 2018 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01292655 | Mar 2011 → Jun 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04461600 | Aug 2020 → Mar 2022 | triple-negative breast carcinoma | Ayala Pharmaceuticals, Inc, | Terminated | No outcome recorded |
| Phase 2 | NCT03691207 | Dec 2018 → Jul 2022 | adenoid cystic carcinoma | Ayala Pharmaceuticals, Inc, | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04111666 ↗ |
| Known as | BMS-906024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01292655 ↗ |
| Action | Inhibit | “BMS-906024 (Notch inhibitor)” NCT01292655 ↗ |
| Modality | Small molecule | “AL101 is a small-molecule that inhibits gamma secretase” NCT03691207 ↗ |
| Route | Intravenous | “BMS-906024 solution intravenously as specified” NCT01292655 ↗ |